Dianthus Therapeutics, Inc. /DE/ Depreciation
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Depreciation of $37.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-04
- Dianthus Therapeutics, Inc. /DE/ depreciation for the quarter ending 2026-06-30 was $37.00K, a 23.33% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ depreciation for the quarter ending 2026-03-31 was $32.00K, a 18.52% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ depreciation for the quarter ending 2025-12-31 was $27.00K, a 3.85% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ depreciation for the quarter ending 2025-09-30 was $27.00K, a 8.00% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ depreciation for fiscal 2025 was $111.00K, a 15.63% increase from fiscal 2024.
- Dianthus Therapeutics, Inc. /DE/ depreciation for fiscal 2024 was $96.00K, a 43.28% increase from fiscal 2023.
- Dianthus Therapeutics, Inc. /DE/ depreciation for fiscal 2023 was $67.00K, a 123.33% increase from fiscal 2022.
- Dianthus Therapeutics, Inc. /DE/ depreciation for fiscal 2022 was $30.00K.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $37.00K 10-Q · filed 2026-08-04 | $69.00K 10-Q · filed 2026-08-04 | $96.00K derived: sum of 3 quarters · filed 2026-08-04 | $123.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $32.00K 10-Q · filed 2026-05-05 | $59.00K derived: sum of 2 quarters · filed 2026-05-05 | $86.00K derived: sum of 3 quarters · filed 2026-05-05 | $116.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $54.00K derived: sum of 2 quarters · filed 2026-03-09 | $84.00K derived: sum of 3 quarters · filed 2026-08-04 | $111.00K 10-K · filed 2026-03-09 |
| 2025-09-30 | $27.00K 10-Q · filed 2025-11-05 | $57.00K derived: sum of 2 quarters · filed 2026-08-04 | $84.00K 10-Q · filed 2025-11-05 | $110.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $30.00K 10-Q · filed 2026-08-04 | $57.00K 10-Q · filed 2026-08-04 | $83.00K derived: sum of 3 quarters · filed 2026-08-04 | $108.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $27.00K 10-Q · filed 2026-05-05 | $53.00K derived: sum of 2 quarters · filed 2026-05-05 | $78.00K derived: sum of 3 quarters · filed 2026-05-05 | $101.00K derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $51.00K derived: sum of 2 quarters · filed 2026-03-09 | $74.00K derived: sum of 3 quarters · filed 2026-03-09 | $96.00K 10-K · filed 2026-03-09 |
| 2024-09-30 | $25.00K 10-Q · filed 2025-11-05 | $48.00K derived: sum of 2 quarters · filed 2025-11-05 | $70.00K 10-Q · filed 2025-11-05 | $90.00K derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $23.00K 10-Q · filed 2025-08-07 | $45.00K 10-Q · filed 2025-08-07 | $65.00K derived: sum of 3 quarters · filed 2025-08-07 | $84.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $22.00K 10-Q · filed 2025-05-12 | $42.00K derived: sum of 2 quarters · filed 2025-05-12 | $61.00K derived: sum of 3 quarters · filed 2025-05-12 | $76.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $39.00K derived: sum of 2 quarters · filed 2025-03-11 | $54.00K derived: sum of 3 quarters · filed 2025-03-11 | $67.00K 10-K · filed 2025-03-11 |
| 2023-09-30 | $19.00K 10-Q · filed 2024-11-07 | $34.00K derived: sum of 2 quarters · filed 2024-11-07 | $47.00K 10-Q · filed 2024-11-07 | $59.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $15.00K 10-Q · filed 2024-08-08 | $28.00K 10-Q · filed 2024-08-08 | $40.00K derived: sum of 3 quarters · filed 2024-08-08 | $46.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $14.00K 10-Q · filed 2024-05-09 | $25.00K derived: sum of 2 quarters · filed 2024-05-09 | $31.00K derived: sum of 3 quarters · filed 2024-05-09 | |
| 2022-12-31 | $11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $17.00K derived: sum of 2 quarters · filed 2024-03-21 | $30.00K 10-K · filed 2024-03-21 | |
| 2022-09-30 | $6.00K 10-Q · filed 2023-11-09 | $19.00K 10-Q · filed 2023-11-09 | ||
| 2021-12-31 | $0.00 8-K · filed 2023-12-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |